A Phase II Study on the Use of Convalescent Plasma for the Treatment of Severe COVID-19- A Propensity Score-Matched Control Analysis

A Phase II Study on the Use of Convalescent Plasma for the Treatment of Severe COVID-19- A Propensity Score-Matched Control Analysis

<b>A</b><b>b</b><b>s</b><b>tract: </b>COVID-19 is a global pandemic associated with increased morbidity and mortality. Convalescent plasma (CP) infusion is a strategy of potential therapeutic benefit. We conducted a multicenter phase II study to evalua...

Full description

Bibliographic Details
Main Authors: Vasiliki Pappa, Anthi Bouchla, Evangelos Terpos, Thomas P. Thomopoulos, Margherita Rosati, Dimitris Stellas, Anastasia Antoniadou, Andreas Mentis, Sotirios G. Papageorgiou, Marianna Politou, Anastasia Kotanidou, Ioannis Kalomenidis, Garyfalia Poulakou, Edison Jahaj, Eleni Korompoki, Sotiria Grigoropoulou, Xintao Hu, Jenifer Bear, Sevasti Karaliota, Robert Burns, Maria Pagoni, Ioannis Trontzas, Elisavet Grouzi, Stavroula Labropoulou, Kostantinos Stamoulis, Aristotelis Bamias, Sotirios Tsiodras, Barbara K. Felber, George N. Pavlakis, Meletios- Athanasios Dimopoulos
Format: Article
Language:English
Published: MDPI AG 2021-04-01
Series:Microorganisms
Subjects:
convalescent plasma
COVID-19
efficacy
SARS-CoV-2 antibodies
Online Access:https://www.mdpi.com/2076-2607/9/4/806

Internet

https://www.mdpi.com/2076-2607/9/4/806

Similar Items